SCHEMBL4111003

SCHEMBL4111003

COc1ccc(NC(=O)Nc2cccc(C#N)c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.74
MEN1 O00255 4/20 0.74
KMT2A Q03164 4/20 0.74
ALDH1A1 P00352 3/20 0.74
TSHR P16473 3/20 0.69
TP53 P04637 1/20 0.69
MAPK14 Q16539 1/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
KDM4E B2RXH2 3/20 0.62
GAA P10253 2/20 0.62
HPGD P15428 1/20 0.62
RAB9A P51151 5/20 0.61
NPC1 O15118 4/20 0.61
MCHR1 Q99705 1/20 0.57
ALOX15 P16050 1/20 0.56
CASP7 P55210 1/20 0.56
HSD17B10 Q99714 1/20 0.56
MAPK1 P28482 3/20 0.56
LMNA P02545 2/20 0.56
POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117473 0.86 MAPT (0.70) MAPTMEN1KMT2AALDH1A1TP53
SCHEMBL4118287 0.85 MEN1 (0.68) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL7248947 0.85 MAPT (1.00) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL29580531 0.85 MAPT (0.87) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL30606801 0.85 MAPT (0.87) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL21295354 0.85 MAPT (0.72) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL666216 0.85 MAPK14 (0.74) MEN1KMT2AALDH1A1TSHRTP53
SCHEMBL6764102 0.85 CXCR1 (0.62) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL4118565 0.84 MAPT (0.67) MAPTMEN1KMT2AALDH1A1TSHR
SCHEMBL4117070 0.84 MAPT (0.80) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.